vs
Side-by-side financial comparison of Hamilton Insurance Group, Ltd. (HG) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $758.9M, roughly 1.9× Hamilton Insurance Group, Ltd.). Hamilton Insurance Group, Ltd. runs the higher net margin — 17.6% vs 10.0%, a 7.6% gap on every dollar of revenue. On growth, Hamilton Insurance Group, Ltd. posted the faster year-over-year revenue change (-1.3% vs -3.5%). Over the past eight quarters, Hamilton Insurance Group, Ltd.'s revenue compounded faster (13.6% CAGR vs -4.7%).
White Mountains Insurance Group is a diversified insurance and related financial services holding company based in Hamilton, Bermuda. Redomiciled from Delaware, United States, on October 25, 1999, the company conducts most of its business through its insurance subsidiaries and other affiliates.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
HG vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $758.9M | $1.5B |
| Net Profit | $133.5M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | — | — |
| Net Margin | 17.6% | 10.0% |
| Revenue YoY | -1.3% | -3.5% |
| Net Profit YoY | 19.7% | 67.8% |
| EPS (diluted) | $1.31 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $758.9M | $1.5B | ||
| Q4 25 | $728.3M | $1.5B | ||
| Q3 25 | $667.6M | $1.6B | ||
| Q2 25 | $740.8M | $1.6B | ||
| Q1 25 | $768.8M | $1.5B | ||
| Q4 24 | $570.5M | $1.6B | ||
| Q3 24 | $512.8M | $1.6B | ||
| Q2 24 | $587.9M | $1.6B |
| Q1 26 | $133.5M | $146.0M | ||
| Q4 25 | $214.6M | $-205.0M | ||
| Q3 25 | $176.4M | $160.0M | ||
| Q2 25 | $267.8M | $145.0M | ||
| Q1 25 | $181.3M | $87.0M | ||
| Q4 24 | $74.4M | $109.0M | ||
| Q3 24 | $61.0M | $359.0M | ||
| Q2 24 | $200.4M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 26.0% | -9.8% | ||
| Q3 25 | 27.0% | 15.2% | ||
| Q2 25 | 36.5% | 14.4% | ||
| Q1 25 | 24.0% | 6.7% | ||
| Q4 24 | 13.4% | 8.1% | ||
| Q3 24 | 12.5% | 13.1% | ||
| Q2 24 | 34.5% | 14.6% |
| Q1 26 | 17.6% | 10.0% | ||
| Q4 25 | 29.5% | -13.6% | ||
| Q3 25 | 26.4% | 10.0% | ||
| Q2 25 | 36.1% | 9.1% | ||
| Q1 25 | 23.6% | 5.8% | ||
| Q4 24 | 13.0% | 6.8% | ||
| Q3 24 | 11.9% | 22.7% | ||
| Q2 24 | 34.1% | 12.1% |
| Q1 26 | $1.31 | $0.55 | ||
| Q4 25 | $1.67 | $-0.78 | ||
| Q3 25 | $1.32 | $0.61 | ||
| Q2 25 | $1.79 | $0.56 | ||
| Q1 25 | $0.77 | $0.33 | ||
| Q4 24 | $0.35 | $0.42 | ||
| Q3 24 | $0.74 | $1.38 | ||
| Q2 24 | $1.20 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $842.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | — |
| Total Assets | $9.9B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $842.5M | — | ||
| Q4 25 | $1.1B | $574.0M | ||
| Q3 25 | $955.1M | $672.0M | ||
| Q2 25 | $985.6M | $599.0M | ||
| Q1 25 | $838.5M | $547.0M | ||
| Q4 24 | $996.5M | $675.0M | ||
| Q3 24 | $957.4M | $763.0M | ||
| Q2 24 | $1.0B | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $149.7M | $8.6B | ||
| Q3 25 | $149.7M | $8.8B | ||
| Q2 25 | $149.7M | $8.9B | ||
| Q1 25 | $150.0M | $9.0B | ||
| Q4 24 | $149.9M | $8.9B | ||
| Q3 24 | $149.9M | $8.7B | ||
| Q2 24 | $149.9M | $8.7B |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.8B | $752.0M | ||
| Q3 25 | $2.7B | $906.0M | ||
| Q2 25 | $2.6B | $733.0M | ||
| Q1 25 | $2.4B | $542.0M | ||
| Q4 24 | $2.3B | $472.0M | ||
| Q3 24 | $2.3B | $493.0M | ||
| Q2 24 | $2.2B | $144.0M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.6B | $12.9B | ||
| Q3 25 | $9.2B | $13.6B | ||
| Q2 25 | $8.9B | $13.5B | ||
| Q1 25 | $8.3B | $13.2B | ||
| Q4 24 | $7.8B | $13.1B | ||
| Q3 24 | $7.8B | $12.8B | ||
| Q2 24 | $7.6B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.05× | 11.49× | ||
| Q3 25 | 0.06× | 9.74× | ||
| Q2 25 | 0.06× | 12.14× | ||
| Q1 25 | 0.06× | 16.52× | ||
| Q4 24 | 0.06× | 18.81× | ||
| Q3 24 | 0.06× | 17.75× | ||
| Q2 24 | 0.07× | 60.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HG
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
